GlassScriptPhysician profile
Salvatore M Buffa
NPI 1346244027
$10,588.42
in general payments reported to CMS, 2019-2025
30 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,261 · 2020: $469 · 2021: $906 · 2022: $618 · 2023: $836 · 2024: $961 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,333.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $4,006.00 | 2019 | |
| Abbvie INC. | $1,428.28 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Romark Laboratories, Lc | $915.16 | 2019-2020 | |
| Boston Scientific Corporation | $696.71 | 2020-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Acquire |
| Pfizer INC. | $469.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $337.50 | 2019-2025 | Eohilia, Entyvio |
| Intercept Pharmaceuticals, INC. | $310.57 | 2019-2023 | Ocaliva |
| Cook Medical LLC | $258.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $220.49 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $180.64 | 2019-2025 | |
| Capsovision, INC. | $158.25 | 2024 | Capsocam Plus |
| Ferring Pharmaceuticals INC. | $155.92 | 2019-2024 | Rebyota |
| Braintree Laboratories, INC. | $147.03 | 2019-2022 | |
| Qol Medical, LLC | $133.44 | 2021-2025 | Sucraid, Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Genzyme Corporation | $124.86 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $113.05 | 2025 | Zenpep |
| Lilly USA, LLC | $70.31 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $67.56 | 2019-2024 | |
| Ardelyx, INC. | $59.31 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $52.78 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $34.80 | 2019-2021 | |
| Alfasigma USA, INC. | $33.57 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $33.41 | 2024 | Iqirvo |
| Shionogi INC | $31.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2025 | Dupixent |
| Curium US LLC | $12.92 | 2022 | |
| Medtronic USA, INC. | $12.70 | 2019 | |
| Ucb, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Buffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.